Canaccord Growth Conference August 2018 confidently live life with ease
Forward-Looking Statements This presentation contains forward-looking statements that are not purely historical regarding Senseonics or its management s intentions, beliefs, expectations and strategies for the future. All forward-looking statements and reasons why results might differ included in this presentation are made as of the date of this presentation, based on information currently available to Senseonics, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Senseonics current expectations are more fully described in Senseonics annual report on Form 10-K for the period ended December 31, 2017, as filed with the Securities and Exchange Commission on March 13, 2018, its most recent quarterly report on Form 10-Q for the period ended June 30, 2018, as filed with the Securities and Exchange Commission on August 8, 2018, and its other reports, each as filed with the Securities and Exchange Commission. Senseonics assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.
Revenue In Billions High Growth Market $8 Market size in billions CGM fastest growing segment $7 $6 $5 $4 $3 $2 $1 2016 2017 $1.2 $1.7 $2.3 $2.2 $4.4 $4.3 $0 CGM 42% YOY Insulin Pumps -4% YOY SMBG* -2% YOY *Based on top 3 companies Close Concerns 2017 Industry Roundup; Management Estimate
Factors Impacting CGM Adoption PATIENT AND OFFICE BURDEN DISCRETION VALUE FORM FACTOR AND DISCOMFORT Leading factors are not adequately addressed with traditional CGM offerings
27% Discontinue CGM Use Within 1 Year Reason N=262 CGM not working properly / accurate enough 71% Problems with adhesive / insertion 61% Too expensive / not covered by insurance 58% Uncomfortable to wear 41% Using pump / don t want two sites on body 33% CGM too big 28% Type 1 Diabetes (T1D) Exchange Registry (2016)
The Goal: Increase Use of CGM Improve glucose control Lower risk of hypoglycemia and take share
The Eversense CGM System Sensor Smart Transmitter Mobile App Fully implanted Small size Up to 180 days On-body vibe alerts Removable/Rechargeable Gentle adhesive Real-time readings every 5 mins No extra receiver Trends, alerts w/ predictive alerts the only CGM: with fully implantable sensor sensor that lasts up to 180 days with on-body vibe alerts with a removable transmitter
2016 for Eversense CGM (90 Day System) 2017 for Eversense XL CGM (180 Day System) 2018 for Eversense CGM (90 Day System)
Europe Distributor Commercialization Contribution Insertions 77% Top 3 countries +60% 1H 18 vs 2017 XL Product 70% Current Users Satisfaction 90% User Rating
Europe Commercial Experience Most important features of the Eversense System: New patients Long sensor life Predictive alerts 30% 25% 20% 50% Readings on phone On-body vibe alerts Traditional CGM users New to CGM FGM users Gentle adhesive
U.S. - Largest Market DiDirreeccttssaaleess 6.0 M (30%) $18 Billion Insulin Taking Patients 600K Pump $2.3B 350K CGM $1.0B have an unmet need Commercialization Strategy Focused on addressable CGM markets National Diabetes Statistics Report, 2017 https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetesstatistics-report.pdf Kelly Close Industry Roundup April 17, 2017 Drawings are not to scale 1
US Launch Execution Approval Distribution Coverage Insertion < 45 Days
Ease and Freedom with Eversense Eliminates site maintenance and management of supplies and reordering Eliminates discomfort and skin irritation associated with acrylate adhesives Eliminates the need to carry a separate receiver Freedom Coin
Ever Mobile Clinic 1,400 HCP and patients visited since approval Boston New York LA San Diego Washington, DC San Antonio Dallas Atlanta Orlando ADA Hands-on diabetes device training and education to U.S. patients and HCPs in their local areas via a custom-built 18-wheeler mobile training facility.
Scalable and Focused HCP Targets Rapid Acting Insulin Rx Volume High Volume CGM CGM-Related Procedure Volume Physician Index = Total Target HCPs: 13,182 Senseonics Primary Targets: 2,600 Initial Core Targets: 300
Index Targets and Sales Force 18 1 15 3 2 4 5 17 8 7 6 14 Current 16 18 Field Sales Representatives 10 9 15 Clinical 13 10 Customer Care/Support EOY Target 11 12 Additional Field Sales Representatives 12
Two Paths to Payment DME CPT Code Device Code Description A9276 A9277 Code 0446T 0447T Sensor; invasive (e.g., subcutaneous) disposable, for use with interstitial continuous glucose monitoring system, 1 unit = 1 day CMS 1500 supply Transmitter; external, for use with interstitial continuous glucose monitoring system Implantation Code Description Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training Removal CMS of implantable 1500 interstitial glucose sensor from subcutaneous pocket via incision Code 0446T 0447T 0448T Implantation Code Description Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training Removal of implantable interstitial glucose sensor from subcutaneous pocket via incision Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation CMS 1500 0448T Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation
# of Covered Lives in Millions Covered Lives Forecast 200 1 st Published Coverage Policy 150 100 50 2018 2019 2020 18
Eversense Pipeline 365 Day Sensor Life 1x/week calibration 365 Day Sensor Life 1x/week calibration On-Demand: Type 2 FGM Long-term wear with no transmitter Type 1 : Gemini FGM +CGM Flash when desired, CGM for peace of mind Same sensor technology. Expanded opportunities.
Senseonics Automated Insulin Delivery IDCL Program 1 2 Eversense CGM / AccuChek Insight / TypeZero algorithm Beta Bionics Program Eversense / ilet Pump and Algorithm incontrol AP System with Eversense Accu Chek Insight Pump ilet Bionic Pancreas System with Eversense *Part of International Diabetes Closed-Loop Trial Pivotal trial in 3 European sites (early 2018)
confidently live life with ease